Astellas Obtains Additional Indication For Prograf in Japan; Pfizer, GSK, Novartis Also Gain
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma received July 7 additional indication approval for its best-selling immunosuppressant Prograf (tacrolimus) for moderate to severe refractory ulcerative colitis in Japan